I've been considering how recent changes in US drug pricing are affecting biopharmaceutical innovation. What should be the main focus to ensure these reforms effectively balance cost control with ongoing innovation? Share your insights by voting below!

What should be the main focus to balance cost control and innovation in US drug pricing reforms?